抗血栓
医学
冠状动脉疾病
重症监护医学
临床试验
癌症
止血
疾病
内科学
作者
Ciro Santoro,Valentina Capone,Mario Enrico Canonico,Giuseppe Gargiulo,Roberta Esposito,Giuseppe D Sanna,Guido Parodi,Giovanni Esposito
出处
期刊:Seminars in Thrombosis and Hemostasis
[Georg Thieme Verlag KG]
日期:2021-07-14
卷期号:47 (08): 950-961
被引量:10
标识
DOI:10.1055/s-0041-1726298
摘要
Improvement in life expectancy of patients suffering from oncohematologic disorders has turned cancer from an acute into a chronic condition, making the management of comorbidities problematic, especially when it comes to both acute and chronic cardiovascular diseases. Treatment-related adverse events and drug-drug interactions often influence the therapeutic approach of patients with active malignancies and cardiovascular disease. Furthermore, tumor cells and platelets maintain a complex crosstalk that on one hand enhances tumor dissemination and on the other hand induces hemostasis abnormalities. Hence, clinicians should move carefully in the intricate land mines established by patients with active cancer under antithrombotic therapy. To date, there is no consensus on the antithrombotic treatment of patients with cardiovascular diseases and concomitant malignancies. The aim of this review is to collect the available scientific evidence, including the latest clinical trials and guidelines, in order to provide guidance on the management of antithrombotic treatment (both antiplatelet and anticoagulant therapy) in cancer patients with either pre-existent or new-onset coronary artery disease. Randomized-controlled trials on antithrombotic treatment in oncologic populations, which by far have thus far been excluded, have to be promoted to supply recommendations in the oncohematologic setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI